Cellebrite
Valuation each multiple against its own 5-year range
Vs. peers Software - Infrastructure
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Cellebrite (CLBT) | 2.71B | 43.08 | 4.67 | 0.00% |
| Microsoft (MSFT) | 3.60T | 25.30 | 7.65 | 0.75% |
| Palantir (PLTR) | 345.74B | 101.05 | 30.79 | 0.00% |
| Oracle (ORCL) | 305.97B | 15.86 | 4.95 | 1.98% |
| Palo Alto Networks (PANW) | 281.87B | 686.64 | 9.83 | 0.00% |
| CrowdStrike (CRWD) | 234.93B | 6,037.89 | 46.05 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 30.5% below Morningstar's fair value estimate.
Fair value
Given the significant price pressure over the last year, Cellebrite DI Ltd might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 18% discount to our quantitative fair value estimate of $14.05 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The company's solid growth bolsters our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 20.6% sits in the top 20% compared with peers globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.
On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 17.2%, for example, sits in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Cellebrite discussion 0 comments